Senseonics Announces Equity Grants To Employees Under Inducement Plan
April 05 2023 - 8:00AM
Business Wire
Senseonics Holdings, Inc. (NYSE American: SENS), a medical
technology company focused on the development and manufacturing of
long-term, implantable continuous glucose monitoring (CGM) system
for people with diabetes, today announced that it had made equity
grants to new employees under its 2019 Inducement Plan (the “Plan”)
in accordance with NYSE American Company Guide Section 711(a).
On April 4, 2023, Senseonics Compensation Committee granted
thirteen new non-executive employees, in the aggregate,
non-qualified stock options to purchase an aggregate of 200,000
shares and a restricted stock unit for 250,000 shares of the
Company’s common stock as an inducement for such employees to join
the Company. The options have an exercise price of $0.5951 per
share, which was the closing price of the Company’s common stock on
the NYSE American on April 4, 2023. 25% of the shares underlying
the options will vest on the first anniversary of the employee’s
start date, with the remainder vesting in monthly installments over
the subsequent three year period, in all cases contingent on such
employee’s continued service with the Company at the applicable
vesting date. 25% of the shares underlying the restricted stock
unit will vest on the first anniversary of the employee’s start
date, with the remainder vesting in six equal installments each May
15th and November 15th over the subsequent 36 month period
following the first anniversary of the start date beginning with
May 15, 2024, subject to the employee’s continuous employment
through the applicable vesting date.
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology
company focused on the development and manufacturing of glucose
monitoring products designed to transform lives in the global
diabetes community with differentiated, long-term implantable
glucose management technology. Senseonics' CGM systems, Eversense®,
Eversense® XL and Eversense® E3 include a small sensor inserted
completely under the skin that communicates with a smart
transmitter worn over the sensor. The glucose data are
automatically sent every 5 minutes to a mobile app on the user's
smartphone.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230405005366/en/
Senseonics Investor Contact Philip Taylor Investor
Relations 415-937-5406 investors@senseonics.com
Senseonics (AMEX:SENS)
Historical Stock Chart
From May 2024 to Jun 2024
Senseonics (AMEX:SENS)
Historical Stock Chart
From Jun 2023 to Jun 2024